Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
Stopped Drug supply issues
Conditions
- Platinum-Refractory Fallopian Tube Carcinoma
- Platinum-Refractory Ovarian Carcinoma
- Platinum-Refractory Primary Peritoneal Carcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian High Grade Serous Adenocarcinoma
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
- PROCEDURE: Computed Tomography
- DRUG: Copanlisib Hydrochloride
- PROCEDURE: Magnetic Resonance Imaging
- DRUG: Olaparib
- DRUG: Paclitaxel
- DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
- DRUG: Topotecan Hydrochloride
Sponsor
National Cancer Institute (NCI)
Collaborators